Loading organizations...

§ Private Profile · 230 E Grand Avenue, Suite S-100. South San Francisco, CA 94080
Clinical-stage biotechnology company developing antibody therapies targeting SIRP for immunological diseases, cancer, and rare diseases.
Based in South San Francisco, California, Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies that target signal regulatory proteins to treat immunological diseases, cancer, and rare conditions. The organization operates with a workforce of approximately 37 employees and manages a development pipeline consisting of one active clinical program, led by the monoclonal antibody ELA026, alongside two preclinical programs. The enterprise has secured substantial venture capital to advance its clinical trials, including a $34.65 million Series A, an $84 million Series B, and a $183 million Series C financing round. This financial backing has been provided by a syndicate of prominent institutional healthcare investors, featuring recognizable firms such as Westlake Village BioPartners, OrbiMed, Redmile Group, and RA Capital. Electra Therapeutics was originally spun out of Star Therapeutics and founded in 2018 by Adam Rosenthal.
Electra Therapeutics has raised $264.0M across 2 funding rounds.
Electra Therapeutics has raised $264.0M in total across 2 funding rounds.
Electra Therapeutics has raised $264.0M across 2 funding rounds. Most recently, it raised $180.0M Series C in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 1, 2025 | $180M Series C | Christoph Broja, Thomas Geninatti | OrbiMed, Westlake Village BioPartners, HBM Healthcare Investments, Mubadala Capital, Sanofi | Announced |
| Feb 1, 2022 | $84M Series B | OrbiMed, Westlake Village BioPartners | Cormorant Asset Management, Cowen Healthcare Investments, Vijay Lathi, RA Capital Management, Amrit Nagpal | Announced |
Electra Therapeutics is a clinical-stage biotechnology company developing first-in-class therapies targeting signal regulatory proteins (SIRP) on immune cells to selectively deplete pathological myeloid cells and T lymphocytes, addressing unmet needs in immunological diseases and cancer[1][2][3][5][6]. Its lead candidate, ELA026, a monoclonal antibody, is in a pivotal Phase 2/3 trial (SURPASS study) for secondary hemophagocytic lymphohistiocytosis (sHLH), a life-threatening inflammatory disorder, and has received FDA Breakthrough Therapy and EMA PRIME designations; the pipeline also includes preclinical programs like ELA822 for broader immunology and inflammation[2][4][5][6]. The company serves patients with severe inflammatory diseases (e.g., sHLH linked to cancer or rheumatological conditions) and potential expansions into blood cancers, Type 1 diabetes, multiple sclerosis, and celiac disease, solving the problem of uncontrolled myeloid and T cell-driven inflammation where current treatments fall short[3][4][6]. Growth momentum is strong, evidenced by $84M Series B (2022), $183M Series C (recent), and rapid advancement from idea to clinic in under three years[2][4][6].
Electra Therapeutics originated in 2018 as a subsidiary under Star Therapeutics' hub-and-spoke model, leveraging antibody drug discovery expertise to target rare diseases, with an initial focus on a single SIRP program[4][7]. Co-founded by Adam Rosenthal, PhD (initial CEO), the idea emerged from pioneering a novel SIRP-targeting mechanism to deplete pathological immune cells, distinct from traditional CD47/SIRPα checkpoints[1][2]. Pivotal early traction included spinning out as operationally independent in 2023, advancing ELA026 to Phase 1b by presenting safety data in cancer-associated sHLH (100% 8-week survival vs. ~50% historical), and securing Series B funding; leadership transitioned to Kathy Dong, PharmD, MBA (current President and CEO) with deep commercialization experience from Gilead's Sovaldi and Harvoni[2][4][6][7].
Electra stands out in biotech through its SIRP-targeted platform, validated clinically for immune modulation:
Electra rides the wave of precision immunology, targeting myeloid/T cell dysregulation in a growing sHLH population amid rising cancer and autoimmune incidences, where treatments lag (e.g., ~50% survival benchmarks)[4][5][6]. Timing aligns with post-pandemic emphasis on rapid rare disease therapies, bolstered by FDA/EMA fast-tracks amid biotech funding recovery for validated assets[5]. Market forces favor it: expanding immuno-oncology/immunology pipelines, unmet needs in hyperinflammatory syndromes, and SIRP's broad applicability across I&I and cancer, positioning Electra to influence ecosystem shifts toward cell-selective depletors over non-specific drugs[1][3][4]. As a Star Therapeutics spinout, it exemplifies efficient biotech incubation models accelerating novel biology to patients[7].
Electra's trajectory points to ELA026 readouts from SURPASS-1 (sHLH) in 2026, potential approvals by 2028 leveraging designations, and ELA822 IND filing soon after, expanding into high-prevalence I&I like MS[4][5][6]. Trends like AI-driven target validation and combo immuno-therapies will amplify SIRP's role, while commercial expertise (e.g., Dong's track record) ensures launch readiness despite years from market. Electra could redefine myeloid-targeting standards, evolving from sHLH pioneer to immunology leader—grounded in science, as its rigorous novel targets pave breakthrough paths[1][6].
Electra Therapeutics has raised $264.0M in total across 2 funding rounds.
Electra Therapeutics's investors include Christoph Broja, Thomas Geninatti, OrbiMed, Westlake Village BioPartners, HBM Healthcare Investments, Mubadala Capital, Sanofi, Cormorant Asset Management, Cowen Healthcare Investments, Vijay Lathi, RA Capital Management, Amrit Nagpal.